OrthoPediatrics reported net revenue of $72.7 million for the three months ended September 30, 2026, up 19% from $61.2 million a year earlier. For the nine months, net revenue rose 16% to $202.5 million, and net cash provided by operating activities was $2.1 million, compared with net cash used of $15.2 million a year earlier.
KIDS · Orthopediatrics Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 42%
- Last earnings
- Oct 27, 2026
- Latest filing
- 10-Q · Oct 28
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Third-quarter revenue rose 19% to a record $72.7 million, and full-year 2026 revenue guidance was raised to $270 to $273 million, representing growth of 14 to 16%. Adjusted EBITDA was a record $6.9 million and free cash flow was positive at $1.6 million, while the company reiterated its approximately $25 million adjusted EBITDA guidance.
OrthoPediatrics Corp. presented an investor deck reporting third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier. The company guides full-year 2026 revenue to $270.0 to $273.0 million, 14% to 16% total growth, and adjusted EBITDA of about $25.0 million.
OrthoPediatrics reported record third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier, and a net loss of $5.9 million. Adjusted EBITDA rose to $6.9 million from $6.2 million, and free cash flow was $1.6 million. The company raised its full-year 2026 revenue guidance to $270.0 million to $273.0 million from $265.0 million to $269.0 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 27, 2026TL;DR. Third-quarter revenue rose 19% to a record $72.7 million, record adjusted EBITDA reached $6.9 million, free cash flow was positive at $1.6 million, and full-year revenue guidance increased to $270.0 million–$273.0 million while adjusted EBITDA guidance remained approximately $25.0 million. OPSB grew above 20% and product launches progressed, but operating expenses increased, the company remained GAAP unprofitable, and cash, short-term investments and restricted cash declined from year-end 2025.
- + Third-quarter revenue increased 19% to a record $72.7 million, including 19% Trauma & Deformity growth, 18% Scoliosis growth and 18% international growth. new
- + Adjusted EBITDA reached a record $6.9 million, compared with $6.2 million in the prior-year quarter.
- + GAAP net loss narrowed to $5.9 million from $11.8 million in the prior-year quarter. new
- + Free cash flow turned positive at $1.6 million, a $5.0 million year-over-year improvement. new
- + Full-year revenue guidance was increased to $270.0 million–$273.0 million, while adjusted EBITDA guidance was reiterated at approximately $25.0 million. new
- − Cash, cash equivalents, short-term investments and restricted cash declined to $44.9 million from $62.9 million at December 31, 2025. new
- − The company remained GAAP unprofitable with a third-quarter net loss of $5.9 million. new
- − Year-to-date free cash flow was approximately $6 million of usage, requiring approximately $6 million of positive free cash flow in the fourth quarter to reach breakeven or better for 2026. new
- − Many super-cycle products remained in limited launch and were not yet meaningfully contributing to growth. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Scoliosis revenue | $19.17M | FY2026 Q3 | +17.9% |
|
|
|||
| Trauma and Deformity revenue | $52.62M | FY2026 Q3 | +19.2% |
|
|
|||
| Adjusted EBITDA non-GAAP | 8.94M | Six Months Ended June 30, 2026 | — |
| Cash, cash equivalents, short-term investments and restricted cash | $47.9M | As of June 30, 2026 | — |
| Free cash flow (non-GAAP) non-GAAP | -8.16M | Six Months Ended June 30, 2026 | — |
| Free cash flow used non-GAAP | $3.1M | the second quarter of 2026 | — |
| Helped a record of nearly 46,000 children | 46,000 | the second quarter of 2026 | — |
| International revenue | $15.7M | the second quarter of 2026 | — |
| Loss per share, diluted (non-GAAP) non-GAAP | -$0.67 | Six Months Ended June 30, 2026 | — |
| Sports Medicine/Other revenue | $1M | the second quarter of 2026 | — |
| U.S. revenue | $54.8M | the second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KIDS
this stock
Orthopediatrics Corp
|
$828.75M | +78.7% | +37.9% | — | 2.9% |
|
ABT
Abbott Laboratories
|
$178.39B | -17.8% | +5.7% | 38.4 | 1.1% |
|
MDT
Medtronic plc
|
$127.84B | +4.0% | +8.4% | 24.6 | 1.8% |
|
SYK
Stryker Corp
|
$118.01B | -11.8% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$60.85B | -56.0% | +12.5% | 17.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 28, 2026
- This year
- 21
OrthoPediatrics reported net revenue of $72.7 million for the three months ended September 30, 2026, up 19% from $61.2 million a year earlier. For the nine months, net revenue rose 16% to $202.5 million, and net cash provided by operating activities was $2.1 million, compared with net cash used of $15.2 million a year earlier.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KIDS | -1.9% | +29.6% | +88.8% | +2.8% | +78.7% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +6.7% | +38.8% | +98.0% | +11.5% | +77.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.